This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
Alzheimer's disease researchers pursue early detection
In the past 25 years of research on Alzheimer's disease, scientists have learned what happens in the afflicted brain but not how to find it early enough to stop it.
A decade-long cascade of important discoveries has brought them to what many researchers call the brink of understanding. Researchers at the University of Colorado School of Medicine are in the hunt, with a drug trial launching and efforts to establish a federally funded research center underway.
When dementia threatens a family's finances
One in three adults will suffer from dementia. Here's how to achieve financial security — and a patient's dignity — when that happens.
Breaking the law may be a sign of dementia
Criminal behavior in older adults, including theft, traffic violations, sexual advances, trespassing and public urination, may be a sign of dementia, researchers say.
There is a subgroup of people, especially older adults who are first-time offenders, who may have a degenerative brain disease underlying their criminal behavior, said Dr. Georges Naasan of the Memory and Aging Center and Department of Neurology at the University of California, San Francisco.
A provocative new way to think about dementia
Just about everything you think you know about Alzheimer's disease and other dementias is wrong. And because the conventional wisdom is so off-track, so are the ways we — both family members and professionals — respond to those with dementia. That's Dr. G. Allen Power's provocative message. He wants us to stop thinking that people with dementia are victims of a terrible debilitating disease that destroys their memory and perception. Instead, Power argues, dementia is "a shift in the way a person experiences the world."
FDA approves combo pill for Alzheimer's disease
Medscape via WebMD
The FDA has approved a combination pill for moderate to severe Alzheimer's disease in people already being treated with both drugs.
The pill, called Namzaric, combines memantine hydrochloride extended-release (Namenda) and donepezil hydrochloride (Aricept).
The two drugs are often prescribed together. About 70 percent of people on Namenda XR are also on Aricept, says David Nicholson, Ph.D., in a statement. He's the senior vice president of global brands R&D for drugmaker Actavis.
Will a cure for Alzheimer's ever be found?
Unless an effective treatment is found, the costs to treat people with Alzheimer's disease will rise to more than $1 trillion by 2050, an increase from current costs estimated at $214 billion, according to data from the nonprofit Alzheimer's Association.
Affecting some 5 million people, Alzheimer's is the most common neurological condition, robbing the afflicted of their memories and so debilitating that many have to live in specialized care facilities.
Miss an issue of AAGP eNews? Click here to visit the AAGP eNews archive page.
Could an insulin nasal spray help treat Alzheimer's?
Medical News Today
Every 67 seconds, someone in the U.S. develops Alzheimer's disease. More than 5 million Americans are living with the condition and it is responsible for around half a million deaths each year. But in a new study, researchers from the Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, reveal they may have found a promising new treatment for the disease — in the form of an insulin nasal spray.
Could retraining the brain's beat cops cure Alzheimer's disease?
Alzheimer's disease is projected to affect 15 million people by mid-century if no cure or prevention is found. Now, a new study in mice offers hope that we are on track to better understanding, and possibly preventing, the disease.
The study, published in the Journal of Clinical Investigation, showed that the poor performance of brain cells known as microglia may explain why nerve cells in the brain die in patients with Alzheimer's. The study also showed that blocking a single molecule on the surface of microglia could reverse memory loss.
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit
Esther Cho, Content Editor, 469.420.2671
Christopher Wood, AAGP, 703.556.9222, x142;
Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.
This edition of the AAGP eNews was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Dec. 30, 2014
Dec. 16, 2014
Dec. 2, 2014
Nov. 18, 2014
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063